Analysts Set Verrica Pharmaceuticals Inc. (NASDAQ:VRCA) PT at $11.75

Shares of Verrica Pharmaceuticals Inc. (NASDAQ:VRCA - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the six analysts that are covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold rating and four have given a buy rating to the company. The average 1-year price target among brokers that have issued a report on the stock in the last year is $11.40.

Several brokerages recently commented on VRCA. Needham & Company LLC reissued a "hold" rating and set a $12.00 price objective on shares of Verrica Pharmaceuticals in a research report on Thursday, October 3rd. Brookline Capital Management reiterated a "hold" rating on shares of Verrica Pharmaceuticals in a report on Wednesday, October 2nd. TD Cowen reduced their price target on shares of Verrica Pharmaceuticals from $15.00 to $10.00 and set a "buy" rating for the company in a research report on Monday. Finally, Royal Bank of Canada lowered their price objective on Verrica Pharmaceuticals from $13.00 to $11.00 and set an "outperform" rating on the stock in a research report on Friday, October 4th.

Institutional Investors Weigh In On Verrica Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in VRCA. Vanguard Group Inc. boosted its stake in shares of Verrica Pharmaceuticals by 0.6% in the 1st quarter. Vanguard Group Inc. now owns 1,268,710 shares of the company's stock worth $7,511,000 after buying an additional 7,609 shares during the last quarter. Simplify Asset Management Inc. purchased a new position in Verrica Pharmaceuticals in the second quarter worth about $2,041,000. Bank of New York Mellon Corp grew its stake in shares of Verrica Pharmaceuticals by 8.1% during the 2nd quarter. Bank of New York Mellon Corp now owns 58,680 shares of the company's stock valued at $428,000 after purchasing an additional 4,393 shares during the period. Renaissance Technologies LLC bought a new stake in shares of Verrica Pharmaceuticals during the 2nd quarter valued at about $332,000. Finally, Rhumbline Advisers increased its position in shares of Verrica Pharmaceuticals by 20.4% during the 2nd quarter. Rhumbline Advisers now owns 26,591 shares of the company's stock valued at $194,000 after purchasing an additional 4,514 shares during the last quarter. Hedge funds and other institutional investors own 42.45% of the company's stock.

Verrica Pharmaceuticals Stock Down 1.9 %

Shares of VRCA traded down $0.03 during mid-day trading on Monday, reaching $1.57. The company had a trading volume of 343,266 shares, compared to its average volume of 437,217. The company has a debt-to-equity ratio of 29.58, a quick ratio of 2.23 and a current ratio of 2.36. The company has a market capitalization of $66.60 million, a price-to-earnings ratio of -0.90 and a beta of 1.45. The firm has a 50-day moving average price of $2.09 and a 200 day moving average price of $5.63. Verrica Pharmaceuticals has a 52 week low of $1.04 and a 52 week high of $11.41.

Verrica Pharmaceuticals (NASDAQ:VRCA - Get Free Report) last released its earnings results on Wednesday, August 14th. The company reported ($0.37) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.06. Verrica Pharmaceuticals had a negative return on equity of 591.84% and a negative net margin of 625.06%. The business had revenue of $5.18 million for the quarter, compared to the consensus estimate of $4.70 million. On average, sell-side analysts forecast that Verrica Pharmaceuticals will post -1.58 EPS for the current year.

About Verrica Pharmaceuticals

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.